GlassScriptPhysician profile
Latha Thanneer
NPI 1306927579
$1,485.50
in general payments reported to CMS, 2019-2025
25 companies · $117 in 2025
The $117 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $343 · 2020: $241 · 2021: $346 · 2022: $165 · 2023: $189 · 2024: $85.00 · 2025: $117.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $391.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $391.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $498.45 | 2019-2024 | |
| Merck Sharp & Dohme LLC | $215.87 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $75.79 | 2019-2025 | Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $66.05 | 2019-2023 | Tradjenta, Jardiance |
| Kowa Pharmaceuticals America, INC. | $54.85 | 2019-2020 | |
| Avanir Pharmaceuticals, INC. | $48.62 | 2019 | |
| Amgen INC. | $48.52 | 2023-2024 | Repatha, Otezla |
| Lundbeck LLC | $46.57 | 2021-2022 | |
| Esperion Therapeutics, INC. | $38.65 | 2021-2023 | Nexletol |
| Irhythm Technologies, INC. | $35.27 | 2024 | Zio Monitor, Zio Xt Patch |
| Alnylam Pharmaceuticals INC. | $33.35 | 2025 | Amvuttra |
| Almatica Pharma LLC | $30.95 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $29.60 | 2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $28.94 | 2019 | |
| Exact Sciences Corporation | $28.57 | 2023 | Cologuard Collection Kit |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abiomed | $26.69 | 2025 | |
| Sanofi-Aventis U.S. LLC | $24.17 | 2022 | |
| Lilly USA, LLC | $23.47 | 2023 | Mounjaro |
| Amarin Pharma, INC. | $21.29 | 2021 | |
| Glaxosmithkline, LLC. | $19.75 | 2019 | |
| Pulmonx Corporation | $19.57 | 2025 | Pulmonx Chartis Tablet Console, Zephyr Delivery Catheter, Zephyr Endobronchial Valve |
| Mylan Specialty L.P. | $19.34 | 2019 | |
| Genzyme Corporation | $17.90 | 2023 | |
| E.R. Squibb & Sons, L.L.C. | $17.39 | 2025 | Eliquis |
| Janssen Pharmaceuticals, INC | $15.88 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Latha Thanneer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.